GLP-1 Weight Loss Medications and Vision: What We Are Seeing in Our Office

At Town Eyecare, we take pride in being partners in your long-term health. Recently, we’ve noticed a significant trend in our community: patients who start GLP-1 weight loss injections (new medications used for type 2 diabetes and obesity) are experiencing vision changes. With millions of Americans (about 12% of U.S. adults) now taking GLP-1 receptor agonists for diabetes or weight management[1], it’s essential to understand why these drugs – while highly effective for blood sugar control and weight loss – might affect your eyesight.

What Are GLP-1 Medications, and Why Might They Affect Vision?
GLP-1 (glucagon-like peptide-1) receptor agonists are medications that help lower blood sugar and support weight loss by stimulating insulin and reducing appetite. They work quickly, often normalizing blood sugar levels and causing substantial weight reduction in a short time frame. However, this rapid change in your body’s chemistry can have unexpected effects on your eyes. One common side effect reported by patients on these GLP-1 weight loss medications is blurred vision or fluctuating clarity that changes throughout the day. The reason is simple but surprising: significant drops in blood sugar can temporarily alter the fluid balance and shape of the eye’s crystalline lens, akin to a camera lens temporarily losing focus as it adjusts. This shift in lens shape causes your vision to seem “off” or blurry. Older patients may notice this more, since as we age the eye’s lens becomes less flexible and takes longer to adapt to sudden changes in blood sugar. The good news is that this type of blurry vision is typically temporary, often subsiding after a few weeks to a few months (usually around 3–4 months) as your body adjusts to the medication’s effects. However, even temporary vision changes are a clear signal that your eyes should be monitored during this time.[jamanetwork.com]

Why a “Wait and See” Approach Isn’t Enough
Beyond simple blurriness, recent clinical data and our own observations have highlighted rare but serious ocular risks that every patient on GLP-1 treatments should be aware of:

• Existing Retinal Health: Rapidly improving your blood sugar is a victory for your overall health, but it can occasionally cause a temporary “flare-up” of existing diabetic retinopathy. In fact, a major clinical trial of a GLP-1 agonist in diabetes reported retinal complications in about 3.0% of patients on the medication vs 1.8% on placebo (an increased risk of ~76%) during the first year of therapy. This led to FDA warnings about diabetic eye disease for this class of drugs. Follow-up studies since have shown mixed results: some analyses suggest a slight increase in retinopathy progression risk in those with severe pre-existing diabetic eye disease, while other large-scale studies found no significant long-term increase in severe retinopathy complications in GLP-1 users versus other diabetes treatments. The key takeaway: if you have diabetes-related eye changes, the rapid sugar drop from these medications could temporarily affect your retinas, so closer eye monitoring is important.
• Optic Nerve Health (NAION):Non-arteritic anterior ischemic optic neuropathy (NAION) is a rare but serious eye condition – essentially a type of “eye stroke” – causing sudden, painless vision loss when blood flow to the optic nerve is impaired. While extremely uncommon, isolated cases have linked GLP-1 receptor agonists to NAION. A recent analysis of patient data and safety reports has estimated the risk to be around 1 in 10,000 patients on certain GLP-1 therapies. Some large studies have observed a 2-fold higher rate of NAION in people on these medications compared to similar patients not on GLP-1 drugs. It’s important to note that these findings are still under investigation, and people with diabetes already have some baseline risk of NAION due to the disease itself. Eye doctors emphasize that there’s not yet proof that GLP-1 medications cause NAION, so you shouldn’t stop a beneficial medication without medical guidance. However, both optometrists and ophthalmologists agree patients and their doctors should be aware of this potential risk and act quickly if any symptoms arise. [mdpi.com]
  
• Macular Health:The macula is the part of the retina responsible for central, detailed vision. Some early research suggests GLP-1 medications might affect the retina’s macula, with a possible link to certain forms of age-related macular degeneration (AMD) in susceptible individuals. Specifically, a few observational studies have raised concern that these drugs may increase the risk of developing “wet” (neovascular) AMD in some patients with diabetes or other risk factors. On the other hand, some other recent analyses have hinted that GLP-1 therapies might even reduce the risk of common (dry) AMD in the long run, possibly due to their positive effects on systemic health. In short, data on AMD are conflicting, and we don’t have definitive answers yet. If you already have AMD or high risk for it, be sure to inform your eye doctor when discussing new GLP-1 therapy so they can advise you appropriately and monitor for any changes in your macular health.

Our Recommended Action Plan for GLP-1 Patients – Monitor Your Eye Health
Because GLP-1 weight loss medications can make you an “at-risk” patient for eye changes, it’s crucial to be proactive about eye care. We follow the latest recommendations from national optometric guidelines to keep your vision safe. Here’s our recommended Action Plan for anyone taking (or planning to start) GLP-1 medications for weight loss or diabetes:

• Baseline Comprehensive Eye Exam: If you are starting a GLP-1 medication, schedule a comprehensive dilated eye exam as a baseline. Ideally, this exam should happen within 12 months before starting therapy, or within the first month after your first dose. A baseline exam checks your retina for signs of diabetic eye disease or age-related macular degeneration and evaluates your optic nerve. Having this reference point will help us detect any changes going forward. [mdpi.com]
  
• Monitor the First 12-Month Window: Most vision changes from GLP-1 medications are seen in the first year of treatment when your body’s metabolism is adjusting. We often recommend more frequent follow-up eye exams during those first 12 months. This might mean scheduling check-ups every few months instead of just an annual exam, especially if you have diabetes or known eye conditions. The goal is to catch any retinal changes early before they can progress or cause permanent effects.
  
• Listen to Your Eyes – Know the Warning Signs: It’s easy to brush off minor vision changes, but don’t ignore new symptoms. If you notice sudden blurry vision that doesn’t quickly clear, new dark spots or “shadows” in your sight, flashes of light or wavy spots, or colors looking faded, call us (or your eye doctor) right away. These could be signs of something more serious like retinopathy bleeding or an optic nerve problem. Rapid action can make a big difference in outcomes. Remember: when in doubt, get it checked out.
  
• Collaborate with Your Health Team: Let your primary care doctor or endocrinologist know about any vision changes you experience. It’s also wise to discuss with your eye doctor that you’re on a GLP-1 therapy so they can tailor your care. In some cases, your medical team might adjust how quickly your blood sugar targets are reached (or how rapidly your medication dose is increased) to allow your eyes to adjust more gradually and safely. A team approach, with your optometrist, primary care physician, and other specialists sharing information, helps ensure you’re getting both the systemic benefits of GLP-1 medications and the necessary safeguards for your eye health.

We Are Here for You
We love seeing our patients take proactive steps toward better health. GLP-1 receptor agonists can be a real game-changer for weight management and diabetes, and for most people the overall health benefits outweigh the eye-related risks. Our job is to make sure that your vision stays clear and healthy as you reach your health goals. Rest assured, our optometrists are up-to-date on the latest research and expert guidance regarding GLP-1 eye health, and we have advanced retinal imaging technology to track even the smallest changes in your retina and optic nerve over time. By staying informed and getting regular diabetic eye exams (especially if you’re starting one of these GLP-1 weight loss injections), you can enjoy the benefits of better health while keeping your eyes safe. If you have started a new health journey recently, let’s make sure your eyes are ready for the ride – we’re here to support you with optometrist-led monitoring for GLP-1 patients every step of the way.

References:

Retinal Physician – Julia H. Joo, MD & Aleksandra V. Rachitskaya, MD, “The Effect of GLP-1RAs in Diabetic Retinopathy” (June 2025). URL: https://www.retinalphysician.com/issues/2025/june/the-effect-of-glp-1ras-in-dr/

American Optometric Association – “GLP-1 Medications and Your Vision” (Feb. 24, 2026). URL: https://www.aoa.org/healthy-eyes/caring-for-your-eyes/glp-1-medications-and-your-vision

American Optometric Association – “GLP-1 Receptor Agonists and Vision Risk” (July 10, 2025). URL: https://www.aoa.org/news/clinical-eye-care/public-health/glp-1-receptor-agonists-and-vision-risk

American Academy of Ophthalmology – Vered Hazanchuk, “Can Ozempic Affect Eye Health? Here’s What Ophthalmologists Want You to Know” (Mar. 18, 2026). URL: https://www.aao.org/eye-health/news/can-ozempic-affect-eye-health-heres-what-ophthalmologists-want-you-to-know